Kezdőlap・Részvénylista・Exelixis Inc

Exelixis Inc

Lezárt

SzektorEgészségügy

52.43 2.64

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

50.91

Maximum

51.21

Fő mutatók
By Trading Economics
Bevétel	1.6M 212M
Értékesítés	18M 629M
P/E Szektor átlag	16.654 57.002
Egy részvényre jutó nyereség	0.82
Profit margin	33.729
Munkavállalók	1,077
EBITDA	-12M 263M

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	+1% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 3.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-717M 13B
Előző nyitás	49.79
Előző zárás	52.43

Hangulat hírek alapján

By Acuity

50%

146 / 340 Rangsor szerint Healthcare

Exelixis Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 13. 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

2026. aug. 12. 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

2026. aug. 11. 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

2026. aug. 10. 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

2026. aug. 8. 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

2026. aug. 7. 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

2026. aug. 6. 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

2026. aug. 5. 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

2026. aug. 4. 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

2026. aug. 3. 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

2026. júl. 31. 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

2026. júl. 30. 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

2026. júl. 29. 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

2026. júl. 28. 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

2026. júl. 27. 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

2026. júl. 24. 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

2026. júl. 22. 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Társak összehasonlítása

Árváltozás

Exelixis Inc Előrejelzés

Célár

By TipRanks

1% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 51.75 USD 1%

Magas 64 USD

Alacsony 41 USD

14 Wall Street elemző 12 hónapos célárain alapulva a(z)Exelixis Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

14 ratings

Vétel

Tartás

Eladás

14 Wall Street elemző célárain alapulva a(z)Exelixis Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

146 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.